| 1 |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J].CA Cancer J Clin, 2018, 68(6): 394-424.
|
| 2 |
Le DT, Kim TW, Van Cutsem E, et al. Phase Ⅱ Open-Label Study of Pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164 [J]. J Clin Oncol, 2020, 38(1): 11-19.
|
| 3 |
FDA. FDA approves first cancer treatment for any solid tumor with a specific genetic feature [EB/OL]. 2017-05-23.
URL
|
| 4 |
Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study [J]. Lancet Oncol, 2017, 18(9): 1182-1191.
|
| 5 |
FDA. FDA grants accelerated approval to ipilimumab for MSI-H or dMMR metastatic colorectal cancer[EB/OL]. 2018-7-11.
URL
|
| 6 |
FDA. FDA grants nivolumab accelerated approval for MSI-H or dMMR colorectal cancer [EB/OL]. 2017-08-01.
URL
|
| 7 |
Andre T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer [J]. N Engl J Med, 2020, 383(23): 2207-2218.
|
| 8 |
FDA. FDA approves pembrolizumab for first-line treatment of MSI-H/dMMR colorectal cancer [EB/OL]. 2020-6-30.
URL
|
| 9 |
Andre T, Shiu K-K, Kim TW, et al. Final overall survival for the phase Ⅲ KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) [J].J Clin Oncol, 2021, 39(15_suppl): 3500.
|
| 10 |
Brunner MC, Chambers CA, Chan FK, et al. CTLA-4-Mediated inhibition of early events of T cell proliferation [J]. J Immunol, 1999, 162(10): 5813-5820.
|
| 11 |
Linsley PS, Greene JL, Brady W, et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors [J]. Immunity, 1994, 1(9): 793-801.
|
| 12 |
Bachmann MF, Köhler G, Ecabert B, et al. Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous [J]. J Immunol, 1999, 163(3): 1128-1131.
|
| 13 |
Matheu MP, Othy S, Greenberg ML, et al. Imaging regulatory T cell dynamics and CTLA4-mediated suppression of T cell priming [J]. Nat Commun, 2015, 6: 6219.
|
| 14 |
Jain N, Nguyen H, Chambers C, et al. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity [J]. Proc Natl Acad Sci U S A, 2010, 107(4): 1524-1528.
|
| 15 |
Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients [J]. Nature, 2014, 515(7528): 563-567.
|
| 16 |
Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition [J]. N Engl J Med, 2017, 377(25): 2500-2501.
|
| 17 |
Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer [J]. Nat Med, 2015, 21(11): 1350-1356.
|
| 18 |
Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential [J]. Nat Rev Gastroenterol Hepatol, 2019, 16(6): 361-375.
|
| 19 |
Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types [J]. Nat Genet, 2019, 51(2): 202-206.
|
| 20 |
Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic [J]. Ann Oncol, 2019, 30(1): 44-56.
|
| 21 |
Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade [J]. Science, 2017, 357(6349): 409-413.
|
| 22 |
Roth MT, Das S. Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy [J]. Expert Rev Anticancer Ther, 2021, 21(2): 229-238.
|
| 23 |
Wang QX, Qu CH, Gao YH, et al. The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers [J]. Exp Hematol Oncol, 2021, 10(1): 2.
|
| 24 |
Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers [J]. Nat Med, 2020, 26(4): 566-576.
|
| 25 |
Yuki S, Bando H, Tsukada Y, et al. Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following spanoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer [J]. J Clin Oncol 2020, 38(15_suppl): 4100.
|
| 26 |
Chen EX, Jonker DJ, Loree JM, et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: The Canadian Cancer Trials Group CO.26 Study [J].JAMA Oncol,2020, 6(6): 831-838.
|
| 27 |
Wang L, Hui H, Agrawal K, et al. m(6) A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy [J]. Embo J, 2020, 39(20): e104514.
|
| 28 |
Segal NH, Cercek A, Ku G, et al. Phase II single-arm study of Durvalumab and Tremelimumab with concurrent radiotherapy in patients with mismatch repair-proficient metastatic colorectal cancer [J]. Clin Cancer Res, 2021, 27(8): 2200-2208.
|
| 29 |
Monjazeb AM, Giobbie-Hurder A, Lako A, et al. A randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation for patients with metastatic colorectal cancer [J]. Clin Cancer Res, 2021, 27(9): 2470-2480.
|
| 30 |
Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with Pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study [J]. Lancet Oncol, 2020, 21(10): 1353-1365.
|
| 31 |
Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis [J]. Cancer Immunol Immunother, 2017, 66(5): 581-592.
|
| 32 |
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline [J]. J Clin Oncol, 2018, 36(17): 1714-1768.
|
| 33 |
Lee JH, Long GV, Menzies AM, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies [J]. JAMA Oncol, 2018, 4(5): 717-721.
|